Floatz logo

Therapeutic Asset Ratings

420 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
ABBV-599 COMPONENT UPADACITINIB
Primary Biliary Cholangitis (PBC)
RenJi HospitalP2CCC (53)
ABBV-599 COMPONENT UPADACITINIB
Primary Sclerosing Cholangitis (PSC)
RenJi HospitalP2CCC (53)
Axitinib
Cytoreductive Nephrectomy
RenJi HospitalP2CCC (53)
Benmelstobart
Malignant Pancreatic Neoplasm
RenJi HospitalP2CCC (53)
Benmelstobart
First-line
RenJi HospitalP2CCC (53)
Catequentinib
First-line
RenJi HospitalP2CCC (53)
Catequentinib
Pancreatic Neoplasm
RenJi HospitalP2CCC (53)
Cytosin-Arabinosid
ESCC
RenJi HospitalP2CCC (53)
Daunorubicin
ESCC
RenJi HospitalP2CCC (53)
Fruquintinib
Non-clear Renal Cell Carcinoma
RenJi HospitalP2CCC (53)
Iparomlimab
HR-positive/HER2-negative Breast Cancer
RenJi HospitalP2CCC (53)
LENVATINIB
Fumarate Hydratase Deficient Renal Cell Carcinoma
RenJi HospitalP2CCC (53)
Pyrotinib
Fumarate Hydratase Deficient Renal Cell Carcinoma
RenJi HospitalP2CCC (53)
Pyrotinib
Hepatic Arterial Infusion Chemotherapy
RenJi HospitalP2CCC (53)
rafutrombopag
Thrombocytopenia
RenJi HospitalP2CCC (53)
rc48-adc
Fumarate Hydratase Deficient Renal Cell Carcinoma
RenJi HospitalP2CCC (53)
rc48-adc
Hepatic Arterial Infusion Chemotherapy
RenJi HospitalP2CCC (53)
Serplulimab
Esophageal Squamous Cell Carcinoma
RenJi HospitalP2CCC (53)
Serplulimab
Non-clear Renal Cell Carcinoma
RenJi HospitalP2CCC (53)
Surufatinib
Esophageal Squamous Cell Carcinoma
RenJi HospitalP2CCC (53)
Tifcemalimab
Unresectable or Advanced Clear Cell Renal Cell Carcinoma That Has Progressed After Previous Immunotherapy
RenJi HospitalP2CCC (53)
Tislelizumab
Fumarate Hydratase Deficient Renal Cell Carcinoma
RenJi HospitalP2CCC (53)
Toripalimab
Cytoreductive Nephrectomy
RenJi HospitalP2CCC (53)
Tuvonralimab
Breast Carcinoma
RenJi HospitalP2CCC (53)
gpc3-car-t cells
Hepatocellular Carcinoma
RenJi HospitalP1/2CCC (53)
Showing 101 to 125 of 420 assets
PreviousPage 5 of 17Next